CTLA4 and melanoma: Historically, ORR is higher for combined CTLA-4 and PD-1 inhibitor therapy than for either single agent CTLA-4 (i.e., ipilimumab), or PD1-inhibitors (i.e., nivolumab or pembrolizumab) in a melanoma population, [20,21,22,23].